Application of miorelaxants in patients with lumbar pain syndromes


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Musculoskeletal pain syndromes (PS) are widespread in the population; they are associated with an increase in the number of cases of temporary disability, a decrease in the quality of life of patients, a significant need for taking medications and, accordingly, the risk of development of undesirable side effects of therapy. Modern tactics of management of such patients assumes the decrease in the intensity of PS as early as possible, providing the possibility of expanding the regime of physical exertion and the timely start of rehabilitation measures. The use of muscle relaxants, in particular baclofen, contributes to an increase in the effectiveness of therapy and a reduction in the duration of treatment. The article discusses available data on the effectiveness of this drug in patients with musculoskeletal PS.

Texto integral

Acesso é fechado

Sobre autores

Pavel Kamchatnov

N.I. Pirogov Russian national medical research university

Email: pavkam7@gmail.com
MD, professor of the Department of neurology, neurosurgery and medical genetics

Saida Khanmurzaeva

Dagestan state medical university

assistant of the Department of nervous diseases, medical genetics and neurosurgery

Aleksandr Chugunov

N.I. Pirogov Russian national medical research university

PhD, associated professor of the Department of neurology, neurosurgery and medical genetics

Naida Khanmurzaeva

Dagestan state medical university

PhD, assistant of the Department of pharmacology

Bibliografia

  1. CDC. National Ambulatory Medical Care Survey: 2010 Summary Tables. Table 9. www.cdc.gov/nchs/data/ahcd/namcs_summary/2010_ namcs_ web_tables.pdf. Accessed March 29, 2016.
  2. Davies C., Nitz A., Mattacola C., Kitzman P., Howell D., Viele K., Baxter D., Brockopp D. Practice patterns when treating patients with low back pain: a survey of physical therapists. Physiother. Theor. Pract. 2014;30(6):399-408.
  3. American College of Radiology. ACR Appropriateness Criteria. Low back pain. 2015. www.acr.org/~/media/ACR/Documents/ AppCriteria/Diagnostic/LowBackPain.pdf. Accessed March 10, 2016.
  4. Hoy D., March L., Brooks P., Blyth F., Woolf A., Bain C., Williams G., Smith E., Vos T., Barendregt J., Murray C., Burstein R., Buchbinder R. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann. Rheum. Dis. 2014;73:968-74.
  5. Есин Р.Г., Есин О.Р., Ахмадеева Г.Д., Салихова Г.В. Боль в спине. Казань: Казанский полиграфкомбинат, 2010. 272 с. [Yesin R.G., Yesin O.R., Akhmadeeva G.D., Salikhova G.V. Back pain. Kazan', 2010. 272 p. (in Russ.)]
  6. Селицкий Г.В., Извозчиков С.Б., Камчатнов П.Р. Синдром хронической тазовой боли. Журн. неврол. и психиатр. им. С.С. Корсакова. 2011;5:71-4. [Selitsky G.V., Izvozchikov S.B., Kamchatnov P.R. Chronic pelvic pain syndrome. S.S.Korsakov J. Neurol. Psych. 2011;5:71-4. (in Russ.)]
  7. Абусуева Б.А., Ханмурзаева С.Б., Камчатнов П.Р. Клинические особенности синдрома хронической тазовой боли у женщин различных возрастных групп. Медицинский алфавит. Неврология и психиатрия. 2016;26(289):26-31. [Abusueva B.A., Khanmurzaeva S.B., Kamchatnov P.R. Clinical features of chronic pelvic pain syndrome in women of different age groups. Medical alphabet. Neuroscience and psychiatry. 2016;26(289):26-31 (in Russ.)]
  8. Gouveia N., Rodrigues A., Ramiro S., Eusébio M., Machado P.M., Canhão H., Branco J.C. The use of analgesic and other pain-relief drugs to manage chronic low back pain: results from a national survey. Pain Practice. 2017;17(3):353-65.
  9. van Tulder M., Koes B., Bouter L. Conservative treatment of acute and chronic nonspecific low back pain. A systematic review of randomized controlled trials of the most common interventions. Spine. 1997;22(18):2128-56.
  10. van Tulder M., Touray T., Furlan A., Solway S., Bouter L.M. Muscle relaxants for nonspecific low back pain: A systematic review within the framework of the cochrane collaboration. Spine. 2003;28(17):1978-92.
  11. Qaseem A., Wilt T., McLean R., Forciea M. for the Clinical Guidelines Committee of the American College of Physicians. Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the American College of Physicians. Ann. Intern. Med. [Published online ahead of print February 14, 2017]. -
  12. Liu P., Guo W., Zhao X., Bai H.P., Wang Q., Wang X.L., Zhang Y.Z. Intrathecal baclofen, a GABAB receptor agonist, inhibits the expression of p-CREB and NR2B in the spinal dorsal horn in rats with diabetic neuropathic pain. Can. J. Physiol. Pharmacol. 2014;92(8):655-60.
  13. Huang D., Huang S., Peers C., Du X., Zhang H., Gamper N. GABAB receptors inhibit low-voltage activated and high-voltage activated Ca(2+) channels in sensory neurons via distinct mechanisms. Biochem. Biophys. Res. Commun. 2015;465(2):188-93.
  14. Narendran R., Duarte R., Valyi A., Eldabe S. The need for and provision of intrathecal baclofen therapy for the management of spasticity in England: an assessment of the Hospital Episode Statistics database. BMJ Open. 2015;5(6):e007517.
  15. Zakrzewska J., Linskey M. Trigeminal neuralgia. BMJ Clin. Evid. 2014;1:43-8.
  16. Fromm G., Terrence C., Chattha A. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann. Neurol. 1984;15(3):240-4.
  17. Al-Quliti K. Update on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options. Neurosciences (Riyadh). 2015;2:107-14.
  18. Ringel R., Roy E. Glossopharyngeal neuralgia: successful treatment with baclofen. Ann. Neurol. 1987;21(5):514-5.
  19. Terrence C., Fromm G., Tenicela R. Baclofen as an analgesic in chronic peripheral nerve disease. Eur. Neurol. 1985;24(6):380-5.
  20. Ewertz M., Qvortrup C., Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta. Oncol. 2015;54(5):587-91.
  21. Hershman D., Lacchetti C., Dworkin R., Lavoie Smith E.M., Bleeker J., Cavaletti G., Chauhan C., Gavin P., Lavino A., Lustberg M.B., Paice J., Schneider B., Smith M.L., Smith T., Terstriep S., Wagner-Johnston N., Bak K., Loprinzi C.L. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014;32(18):1941-67.
  22. Somberg J., Molnar J. Retrospective evaluation on the analgesic activities of 2 compounded topical creams and voltaren gel in chronic noncancer pain. Am. J. Ther. 2015;22(5):342-9.
  23. Keppel-Hesselink J., Kopsky D., Sajben N. Vulvodynia and proctodynia treated with topical baclofen 5% and palmitoylethanolamide. Arch. Gynecol. Obstet. 2014;290(2):389-93.
  24. Safaeian P., Mattie R., Hahn M., Plastaras C.T., McCormick Z.L. Novel treatment of radicular pain with a multi-mechanistic combination topical agent: A case series and literature review. Anesth. Pain Med. 2016;6(2):e33322
  25. Zaringhalam J., Manaheji H., Rastqar A., Zaringhalam M. Reduction of chronic non-specific low back pain: A randomised controlled clinical trial on acupuncture and baclofen. Chin. Med. 2010;5:15.
  26. Карнеев А. Н., Соловьева Э.Ю., Федин А.И. Эффективность и переносимость комбинированной терапии месиполом и баклосаном пациентов с хроническим рецидивирующим вертеброгенным болевым синдромом. Журн. неврол. и психиатр. им. С.С. Корсакова. 2008;108(9):48-51. [Karneev A.N., Solov'eva E.Yu., Fedin A.I. Efficacy and tolerability of the combined therapy with mesipol and baclosan in chronic recurrent vertebrogenic pain syndrome. S.S.Korsakov J. Neurol. Psych. 2008;108(9):48-51 (in Russ.)]
  27. Крючкова С.В. Эффективность баклосана в комплексной терапии мышечно-тонического болевого синдрома в раннем послеоперационном периоде у больных, перенесших микродискэктомию. Журн. неврол. и психиатр. им. С.С. Корсакова. 2015;115(3):41-4. [Kryuchkova S.V. Efficacy of baclosan in combined therapy of muscular-tonic pain syndrome in the early postoperative period in patients after microdiscectomy. S.S.Korsakov J. Neurol. Psych. 2015;115(3):41-4. (in Russ.)]
  28. Батышева Т.Т., Бойко А.Н., Зайцев К.А. и др. Применение баклосана в комплексной терапии мышечно-тонического и миофасциального болевого синдрома у пациентов с дорсопатией. Журн. неврол. и психиатр. им. С.С. Корсакова. 2008;108(6):34-6. [Batysheva T.T., Boiko A.N., Zaitsev K.A. et al. The use of baclosan in the complex therapy of muscle-tonic and myofascial pain syndromes in patients with dorsopathy. S.S.Korsakov J. Neurol. Psych. 2008;108(6):34-6 (in Russ.)]
  29. Корешкина М. И. Баклосан (баклофен) в лечении болей в спине. Результаты многоцентрового исследования BRAVO. Журн. неврол. и психиатр. им. С.С. Корсакова. 2009;8:55-7. [Koreshkina M.I. Baclosan (baclofen) in the treatment of back pains: results of a multicenter study BRAVO. S.S.Korsakov J. Neurol. Psych. 2009;8:55-7. (in Russ.)]
  30. Федотова А.В., Вознесенская Т.Г. Баклофен при лечении болей в спине (мышечно-тонических и миофасциальных болевых синдромов). Леч. нервн. болезней. 2004;2:19-22. [Fedotova A.V., Voznesenskaya T.G. Baclofen in the treatment of back pain (muscletonic and myofascial pain syndromes). Treat. Nervol. Dis. 2004;2:19-22 (in Russ.)]
  31. Есин Р.Г., Лотфуллина Н.З., Есин О.Р. Поясничная боль: остеохондроз или остеоартроз? Журн. неврол. и психиатр. им. С.С. Корсакова. 2015;115(10/2):78-82. [Yesin R.G., Lotfullina N.Z., Yesin O.R. Back pain: osteochondrosis or osteoarthritis? S.S.Korsakov J. Neurol. Psych. 2015;115(10 Pt 2):78-82 (in Russ.)]

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2017